Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection

Background Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the fo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of translational medicine Jg. 19; H. 1; S. 272 - 16
Hauptverfasser:	Petruccioli, Elisa, Najafi Fard, Saeid, Navarra, Assunta, Petrone, Linda, Vanini, Valentina, Cuzzi, Gilda, Gualano, Gina, Pierelli, Luca, Bertoletti, Antonio, Nicastri, Emanuele, Palmieri, Fabrizio, Ippolito, Giuseppe, Goletti, Delia
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 26.06.2021 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Antibody response Antigens Biological markers Biomarkers Biomedical and Life Sciences Biomedicine Blood Chemokines Clinical trials Coronaviruses COVID-19 COVID-19 Vaccines Cytokines Disease Granulocyte colony-stimulating factor Granulocyte-macrophage colony-stimulating factor Growth factors Health aspects Humans Identification and classification Immune response Immunity Immunogenicity ImmunoVirology and ImmunoOncology Infections Infectious diseases Interleukin 10 Interleukin 12 Interleukin 13 Interleukin 2 Interleukin 4 Interleukin 5 Interleukin 6 Interleukin 7 Interleukin 8 Interleukin 9 IP-10 Lymphocytes T Medicine/Public Health Monocyte chemoattractant protein 1 Patients Peptides Proteins RNA, Viral SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 T-cell Tuberculosis Vaccines Variables Vascular endothelial growth factor Viral antigens Italy COVID-19 Spike SARS-CoV-2 IFN-γ Immune response T-cell Whole-blood Biomarkers IP-10 Immunity
ISSN:	1479-5876, 1479-5876
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!